CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies ...
Syros Pharmaceuticals Inc SYRS revealed on Tuesday that the SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint of complete response rate. The trial assessed tamibarotene in ...
Every time Joanna publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...
Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and wiping 85% off the share price of the beleaguered biotech. The phase 3 trial was ...
Syros Pharmaceuticals’ SYRS shares plunged 61.7% on Aug 13, after the company discontinued enrollment in the mid-stage acute myeloid leukemia (AML) study of its investigational candidate, tamibarotene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback